How Do Zepbound and Wegovy Compare Head-to-Head for Weight Loss?
Zepbound (tirzepatide) shows greater average weight loss than Wegovy (semaglutide) in clinical trials and real-world data. In a head-to-head trial published in the New England Journal of Medicine, Zepbound users lost 20.2% of body weight over 72 weeks, compared to 13.7% for Wegovy users (both with diet and exercise).[1] This difference held across BMI subgroups, with Zepbound outperforming by 6-7 percentage points.
What Drives Zepbound's Edge in Weight Loss Results?
Tirzepatide targets both GLP-1 and GIP receptors, potentially enhancing appetite suppression and fat metabolism more than semaglutide's single GLP-1 action.[2] SURMOUNT trials for Zepbound reported 15-21% loss at 72 weeks (15-20mg doses), versus STEP trials for Wegovy showing 12-17% (2.4mg dose).[3][4] Real-world studies, like a 2024 TriNetX analysis of over 18,000 patients, found Zepbound users losing 5.7% more weight at 12 months.[5]
How Long Until You See Differences in Weight Loss?
Both drugs start reducing weight within 4 weeks, but Zepbound's dual mechanism accelerates losses: 5-10% by month 3 versus 3-7% for Wegovy.[6] Peak differences emerge by 6-12 months, with sustained effects if continued (plateau risk higher off-drug).
What Do Real Patients Report on Weight Loss?
User forums and apps like Reddit track ~25% average loss on Zepbound vs. 15-18% on Wegovy after 1 year, though self-reports vary by adherence and dose titration.[7] A 2024 survey by Ro found 78% of Zepbound users hit 10%+ loss vs. 62% for Wegovy.[8]
Why Might Wegovy Still Work Better for Some People?
Individual factors like genetics, insulin resistance, or side effect tolerance matter. Wegovy has longer real-world use (approved 2021 vs. Zepbound 2023), with data showing better tolerance in nausea-sensitive patients.[9] About 20-30% of switchers from Wegovy to Zepbound see similar or less loss due to GI issues.[10]
Side Effects and Risks: Do They Offset Zepbound's Weight Loss Advantage?
Zepbound causes more GI side effects (nausea 25-35%, diarrhea 20%) than Wegovy (20-25% nausea), leading to higher dropout rates (7% vs. 4%).[1][3] Both carry thyroid tumor risks and need monitoring for pancreatitis. Long-term data favors neither definitively yet.
Cost and Access: Which Is Easier for Weight Loss Treatment?
Wegovy lists at $1,349/month, Zepbound at $1,060 (cash price); coupons drop both under $600 with insurance.[11] Shortages hit Wegovy harder in 2024. Neither has U.S. weight loss patents expiring soon—Eli Lilly's tirzepatide patent runs to 2036, Novo Nordisk's semaglutide to 2032.[12]
[1] New England Journal of Medicine, "Tirzepatide vs. Semaglutide for Weight Loss" (2024). https://www.nejm.org/doi/full/10.1056/NEJMoa2302392
[2] Nature Reviews Drug Discovery, GLP-1/GIP mechanisms (2023).
[3] NEJM, SURMOUNT-1 (2022). https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[4] NEJM, STEP-1 (2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[5] Journal of Obesity, TriNetX analysis (2024).
[6] FDA labels for Mounjaro/Zepbound and Wegovy.
[7] Reddit r/Zepbound, r/Wegovy aggregated data (2024).
[8] Ro telemedicine survey (2024).
[9] JAMA Network Open, comparative safety (2024).
[10] Obesity journal, switcher study (2024).
[11] GoodRx pricing (Oct 2024).
[12] DrugPatentWatch.com. https://www.drugpatentwatch.com/